Global

Donald Macarthur and Dr. Meriem Bouslouk-Marx discuss post-approval findings of national committees in Europe charged with deciding the best strategy to use a new COVID-19 vaccine in their populations.

Can private sector serve public interests in battling rare diseases?

How the unfolding of notable infringement claim could alter commercial approaches for players in wider CBD treatment field.

Laura Barrell, Senior Associate at VWV, outlines how the UK is emerging from the trials of Brexit and COVID to take a leading international role in the future of pharma and healthcare.

Sam Pearce, SVP, Head of Europe and International at Jazz Pharmaceuticals, talks about joining the company during a transformative period and how she is working to foster a bold and collaborative culture to expand Jazz’s footprint in Europe and beyond.

There is considerable variation in the regulatory approach to medical cannabis between European countries. Yet, despite the complexity, there are clear routes to market, reports Peter Kohut.

On December 24, 2020, the UK finally agreed a Trade and Cooperation Agreement (TCA) with the EU. Cliodhna McDonough offers some initial thoughts on the implications of the TCA on the life sciences sector.

EU tasked with translating bold declarations into reality.

Donna L. LaVoie outlines the takeaways of a recent industry webinar discussing global trends on public and private markets, JPM virtual week, and more. 

Must find common ground between digitalization and protection laws.

Must maintain trust in face of customary, non-pandemic challenges.

Universal strategy push elicits range of constituency views.

Orphan drug incentives set to remain in place in Europe.

Christine Phillips looks at how an increase in protectionism across the EU member states with respect to foreign direct investment impacts the life sciences sector.

Budget battle threatens efforts to bolster Europe’s pharma strategy.

Andrew Hood and Cliodhna McDonough look at the key issues necessary to support business and the community in developing a long-term and sustainable response to the challenges highlighted by COVID-19.

Click here to download the August 2020 edition.

Stephanie Hill looks at the efforts made by patient solutions providers in the UK to build and support services outside the hospital environment during the pandemic.

Pandemic sparks call for European manufacturing renaissance.

Industry prospects at mercy of public discourse, policy shifts.

Pandemic fallout could spell fundamental business and policy shifts.

Ali Mosawi writes about the misconceptions of Iraq's often inhospitable landscape, the essential role of international expertise in driving growth, and how the sector has adapted to meet the challenges of the COVID-19 pandemic.

With coronavirus a stark backdrop, European initiative pushes for “fair” drug prices to spur investment in pharma innovation.

Medical devices manufacturers and pharma companies alike should review their compliance strategies as the EU Medical Device Regulation Date of Application approaches.

The collection of source plasma for new therapies igniting debate.

Jianan Huang outlines the market prospects for first-line treatments for liver cancer treatment in China.

The Medicines and Medical Devices Bill was recently introduced to the UK House of Commons. Does it provide the confidence that the UK is still a leading country for life sciences? Cliodhna McDonough reports.

New OECD study doesn’t shed much light on the effectiveness of managed entry agreements for drug access.

Natalie Douglas talks about her experience in the area of managed and expanded access and her new venture, RareiTi.

ISPOR has published its third issue of the top trends in HEOR. Leela Barham takes a look at how the list has changed over time.